Akèy › Kansè renn (Kasinom selil renn) › Kalifòni
Etid klinik pou Kansè renn (Kasinom selil renn) nan Kalifòni
51 etid pou Kansè renn (Kasinom selil renn) ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
- Los Angeles20 etid
- Baldwin Park16 etid
- San Diego14 etid
- San Francisco11 etid
- Santa Monica8 etid
- Irvine7 etid
- Sacramento6 etid
- Newport Beach5 etid
- Mountain View5 etid
- Orange5 etid
- Santa Rosa4 etid
- Roseville4 etid
- San Jose3 etid
- Upland3 etid
- San Mateo3 etid
- Modesto3 etid
- Santa Maria3 etid
Tèks ofisyèl etid la (Anglè)
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, San Diego
- Research Site, Santa Monica
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Los Angeles Site, Duarte
- NEO-811 San Diego Site, San Diego
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT07300241Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
- UCSF Medical Center at Mission Bay ( Site 5008), San Francisco
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT07049926A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- University of California San Diego Moores Cancer Center, La Jolla
- Cedars-Sinai Medical Center, Los Angeles
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- PCR Oncology, Arroyo Grande
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- ak 20 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #59, Santa Barbara
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
- University of California Irvine, Orange
- Stanford, Palo Alto
- University of California San Francisco, San Francisco
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05287945Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
- City of Hope, Duarte
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07594106DESTINY-PANTUMOUR04
- Research Site, San Diego
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- University of California San Diego, La Jolla
- Stanford University, Palo Alto
- UCLA Medical Center, Santa Monica
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Precision NextGen Oncology, Beverly Hills
- OPN Healthcare, Inc, Glendale
- University of Southern California, Los Angeles
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Local Institution - 0178, Palo Alto
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07293351Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
- University of California San Diego, La Jolla
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06863311Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- PCR Oncology, Arroyo Grande
- Tower Cancer Research Foundation, Beverly Hills
- Mills-Peninsula Medical Center, Burlingame
- ak 16 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
- City of Hope Investigational Drug Services (IDS), Duarte
- UC San Diego Medical Center - Encinitas, Encinitas
- ak 13 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07227415TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
- USC Norris Comprehensive Cancer Center, Los Angeles
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04969315A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- City of Hope Medical Center, Duarte
- University of California San Diego Medical Center, Moores Cancer Center, La Jolla
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07195916ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of California, San Diego, La Jolla
- Hoag Memorial Hospital Presbyterian, Newport Beach
- Redwood City, Redwood City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Sutter Auburn Faith Hospital, Auburn
- Tower Cancer Research Foundation, Beverly Hills
- City of Hope Comprehensive Cancer Center, Duarte
- ak 23 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06661720Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT05830058Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06582017Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06432036Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
- City of Hope National Medical Center, Duarte
- Chao Family Comprehensive Cancer Center, Orange
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT05361720A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Community Cancer Institute, Clovis
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT04895709A Study of MGC026 in Participants With Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
- City of Hope Medical Center, Duarte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07226544A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Providence Medical Foundation ( Site 0141), Fullerton
- USC Norris Comprehensive Cancer Center ( Site 0126), Los Angeles
- Cedars-Sinai Medical Center ( Site 0112), Los Angeles
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT07227402Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Duarte
- Xencor Investigative Site, Sacramento
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT05433142Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- City of Hope, Duarte
- Los Angeles Cancer Network, Glendale
- California Research Institute, Los Angeles
- ak 3 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
- University of California, San Francisco, San Francisco
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT07043608Imaging of Solid Tumors Using 18F-TRX
- University of California, San Francisco, San Francisco
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT06942104Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
- City of Hope Medical Center, Duarte
- City of Hope Medical Center, Irvine
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT07128680A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- John Wayne Cancer Institute (JWCI), Santa Monica
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT03972657Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
- University of California, Davis, Sacramento
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06101290An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 15, 2026 · NCT06447103Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- Start Lacn, Los Angeles
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT07517198Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 9, 2026 · NCT07037004KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- University of Southern California, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT06026410Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- City of Hope, Irvine
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT06053658Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.